Skip to main content

Resumption Recommendation Expected

Officials in the US are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine, the Washington Post reports.

Officials from the Food and Drug Administration and Centers for Disease Control and Prevention recommended earlier this month that inoculations with J&J's vaccine be paused while they investigated reports of rare, but serious blood clots combined with low blood platelet levels.

According to the Post, officials are expected to recommend that a new warning statement about the possibility of the rare complication be added to fact sheets about the vaccine. It notes that that would be in line with what European regulators announced earlier this week. The European Medicines Agency said that though the vaccine may be associated with an increased risk of blood clots, its benefit of preventing COVID-19 outweighs the risk.

The Post adds that an official announcement is expected following the meeting Friday of a CDC advisory panel.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.